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ABSTRACT
Glycyrrhiza inflata has been used as a traditional medicine with
anti-inflammatory activity; however, its mechanism has not
been fully understood. Licochalcone A is a major and bioge-
netically characteristic chalcone isolated from G. inflata. Here,
we found that licochalcone A strongly inhibited tumor necrosis
(TNF)--induced nuclear localization, DNA binding activity, and
the transcriptional activity of nuclear factor-B (NF-B).
Whereas licochalcone A had no effect on the recruitment of
receptor-interacting protein 1 and IB kinase  (IKK) to TNF
receptor I by TNF-, it significantly inhibited TNF--induced IB
kinase complex (IKK) activation and inhibitor of nuclear fac-
tor-B degradation. It is interesting that we found that the
cysteine residue at position 179 of IKK is essential for licoch-
alcone A-induced IKK inhibition, because licochalcone A failed
to affect the kinase activity of the IKK (C179A) mutant. In
contrast, a structurally related compound, echinatin, failed to
inhibit TNF--induced IKK activation and NF-B activation,
suggesting that the 1,1-dimethy-2-propenyl group in licochal-
cone A is important for the inhibition of NF-B. In addition,
TNF--induced expression of inflammatory cytokines CCL2/
monocyte chemotactic protein-1and CXCL1/KC was clearly
inhibited by licochalcone A but not echinatin. Taken together,
licochalcone A might contribute to the potent anti-inflammatory
effect of G. inflata through the inhibition of IKK activation.
Tumor necrosis factor (TNF)- is mainly produced by mac-
rophages but also by a broad variety of other tissues, includ-
ing lymphoid cells, mast cells, endothelial cells, fibroblasts,
and neuronal tissues (Chen and Goeddel, 2002; Wajant et al.,
2003). TNF- is a pleiotropic proinflammatory cytokine with
a wide range of biological effects. TNF- participates in the
inflammatory effect by inducing various inflammatory cyto-
kines, including CCL2/monocyte chemotactic protein
(MCP)-1, CXCL1/KC, and interleukin-6, through the activa-
tion of a transcription factor, nuclear factor-B (NF-B) (Mu-
kaida et al., 1990; Zhang et al., 1990; Ping et al., 1999).
Therefore, dysregulated TNF- function is implicated in the
pathological process of many diseases, including rheumatoid
arthritis, Crohn’s disease, and several neurological diseases
(Liu, 2003).
In mammals, the NF-B family has five members: RelA/
p65, RelB, c-Rel, NF-B1/p50, and NF-B2/p52 (Hayden and
Ghosh, 2008). The NF-B p50/p65 heterodimer is a typical
member of the Rel family of transcription factors that regu-
late diverse cellular functions, such as immune response, cell
growth, and development. In the canonical NF-B pathway,
TNF- activates the IB kinase complex (IKK) that is com-
posed of two catalytic subunits, IKK and IKK, and a reg-
ulatory subunit, IKK. In unstimulated cells, NF-B remains
inactive in the cytoplasm through the association with inhib-
itor proteins of the IB family (DiDonato et al., 1997; Mer-
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curio et al., 1997; Zandi et al., 1997; Yamaoka et al., 1998).
Activated IKKs phosphorylate IBs, leading to their ubiquiti-
nation and proteosomal degradation. These events release
NF-B dimers in the cytosol, allowing them to translocate to
the nucleus where they enhance the transcription of target
genes (Palombella et al., 1994; DiDonato et al., 1996).
So far, the molecules involved in the TNF- signaling path-
way have been identified, and the signal transduction mech-
anism leading to NF-B activation has been fully understood.
As with other signaling ligands, TNF- exerts its cellular
effect through two distinct receptors, a 55-kDa receptor 1
(TNFRI) and a 75-kDa receptor (TNFRII) (Heller et al., 1990;
Barrett et al., 1991). TNFRI is ubiquitously expressed and
seems to be the key mediator of TNF- signaling in the
majority of cells (Ryffel et al., 1991). Binding of TNF- to
TNFRI on the cell surface triggers the trimerization of recep-
tors, and the exposed intracellular domain of TNFRI is rec-
ognized by a death domain-containing adaptor protein, the
TNF receptor-associated death domain (TRADD) (Hsu et al.,
1995). TRADD acts as a scaffold protein that recruits a
serine/threonine kinase, receptor-interacting protein (RIP),
and an adapter protein TNF receptor-associated factor
(TRAF) 2 (Rothe et al., 1994; Hsu et al., 1996; Liu et al.,
1996). Consequently, it activates the downstream IKK com-
plex, leading to NF-B activation (Palombella et al., 1994;
DiDonato et al., 1996, 1997; Mercurio et al., 1997; Zandi et
al., 1997; Yamaoka et al., 1998).
Liquorice root has been used as a traditional medicine in
the East and West for the treatment of gastric ulcer, bron-
chial asthma, and inflammation (Shibata, 2000). Licochal-
cone A is a major and biogenetically characteristic chalcone
isolated from the root of Xinjiang liquorice (Glycyrrhiza in-
flata) (Hatano et al., 1988). A previous study showed that
licochalcone A possessed radical-scavenging effects (Haragu-
chi et al., 1998), antileishmanial activity, and antimicrobial
activity, inhibiting the growth of Staphylococcus aureus and
the activity of Helicobacter pylori (Chen et al., 1993; Fukai et
al., 2002). Furthermore, licochalcone A has been reported to
inhibit the production of chemical mediators, such as prosta-
glandin E2 and interleukin-1-induced cytokines in human
skin fibroblasts (Furuhashi et al., 2005). Therefore, drugs
consisting only of licochalcone A are expected to have a po-
tent anti-inflammatory effect; however, the detailed anti-
inflammatory mechanism has not been clarified.
In this study, we focused on the effect of licochalcone A on
the TNF- signaling pathway. It is interesting that we ob-
served that licochalcone A significantly inhibited TNF--in-
duced NF-B activation by preventing IKK activation. As a
result, licochalcone A induced the suppression of NF-B-
regulated gene products and led to the inhibition of TNF--
induced inflammation.
Materials and Methods
Reagents. Licochalcone A and echinatin were donated by Min-
ophagen Pharmaceutical Co. Ltd. (Akasaka, Tokyo) (Hatano et al.,
1988; Shibata, 2000). Murine TNF- was purchased from PeproTech
(Rocky Hill, NJ). Antibodies recognizing p65, lamin, IB, TNFRI,
IKK, IKK, IKK, TRADD, TRAF2, -actin, and c-Myc were pur-
chased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). The
antibody against RIP1 was purchased from BD Biosciences Trans-
duction Laboratories (Lexington, KY). Horseradish peroxidase-con-
jugated anti-rabbit and anti-mouse polyclonal IgG antibodies were
purchased from Dako-Japan (Tokyo, Japan).
Plasmids. Human RIP1 cDNA and IKK cDNA were subcloned
into pCMV5. The expression vector for His6-tagged ubiquitin was a
gift from Dr. Dirk Bohmann (University of Rochester, Rochester,
NY). Mutagenesis of amino acid residues in IKK C179A was per-
formed using a site-directed mutagenesis kit (Stratagene, La Jolla,
CA).
Cell Culture. NIH-3T3 stably expressing the NF-B-dependent
luciferase reporter plasmid (KF8) was established as described pre-
viously (Funakoshi-Tago et al., 2008). The NF-B-responsive lucif-
erase construct encodes the firefly luciferase reporter gene under the
control of a minimal CMV promoter and five repeats of the NF-B
transcriptional response element (5'-GGGGACTTTCCC-3') (Strat-
agene). NIH-3T3 cells, KF8 cells, and HEK293T cells were grown in
Dulbecco’s modified Eagle’s medium (Nissui, Tokyo, Japan) supple-
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Fig. 1. Licochalcone A (LicoA) potently in-
hibits TNF--induced NF-B activation. A,
structure of licochalcone A. B, NIH-3T3
cells were pretreated with different concen-
trations of licochalcone A or DMSO (0.1%)
for 1 h at 37°C after stimulation with
TNF- (10 ng/ml) for 30 min, and nuclear
extracts were prepared. NF-B DNA bind-
ing activity was measured by electro-
phoretic mobility shift assay with a radio-
labeled probe containing a consensus
NF-B binding site (5-AGTTGAGGG-
GACTTTCCCAGG-3). C, for supershift as-
say, nuclear extracts from cells treated
with TNF- (10 ng/ml) for 30 min were
incubated in the presence of 1 g of anti-
p65 antibody. D, NIH-3T3 cells (5  104)
were preincubated with various concentra-
tions of licochalocne A for 1 h at 37°C. After
treatment with TNF- (10 ng/ml) for 12 h,
cell viability was analyzed by trypan blue
exclusion tests using a cell viability ana-
lyzer (Beckman Coulter).
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mented with 10% heat-inactivated fetal bovine serum (FBS) (Bio-
west, Nuaillé, France), 100 U/ml penicillin G, 100 g/ml streptomy-
cin, and 4 mM L-glutamine.
Electrophoretic Mobility Shift Assay. Consensus double-
stranded oligodeoxynucleotide probes for NF-B (5'-TAGTT-
GAGGGGACTTTCCCAGGC-3') were radioactively labeled using
[-32P]ATP and T4 polynucleotide kinase, as described previously
(Funakoshi-Tago et al., 2003). Then, 2 g of nuclear extract was
incubated with a -32P-labeled double-stranded oligonucleotide
probe in buffer containing 10 mM HEPES-KOH, pH 7.8, 420 mM
KCl, 0.1 mM EDTA, pH 8.0, 5 mM MgCl2, 20% glycerol, 25 mM
dithiothreitol, 10 g/ml aprotinin, 10 g/ml leupeptin, and 5 mM
Na3VO4. The binding reaction was carried out at 30°C for 20 min
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Fig. 2. Licochalcone A potently inhibits TNF--induced nuclear
translocation of NF-B p65. A, NIH-3T3 cells were pretreated with
licochalcone A (20 M) or DMSO (0.1%) for 1 h at 37°C after
stimulation with TNF- (10 ng/ml) for the indicated periods. Nu-
clear extracts were prepared and immunoblotted with anti-p65
antibody or anti-lamin antibody (as a control). B, NIH-3T3 cells
were cultured on sterile coverslips and pretreated with licochal-
cone A (20 M) or DMSO (0.1%) for 1 h at 37°C after stimulation
with TNF- (10 ng/ml) for 30 min. Cells were fixed in 4% parafor-
maldehyde and the localization of p65 was visualized with an
antibody (green). 4,6-Diamidino-2-phenylindole (DAPI; blue) was
also applied to visualize nuclei. C, NIH-3T3 cells expressing pNF-
B-Luc (KF8 cells) were pretreated with different concentrations
of licochalcone A or DMSO (0.1%) for 1 h at 37°C after stimulation
with TNF- (10 ng/ml) for 5 h. NF-B-dependent luciferase activ-
ity was normalized to the protein amounts. Data are the mean 
S.D. of the relative luciferase activities of pNF-B-Luc in four





0   5  15  30  60TNFα (min)
DMSO Lico A
0   5  15  30  60 
p-GST-IκBα
IB: IKKγ





DMSO Lico A 













Fig. 3. Licochalcone A significantly inhibits TNF--
induced IKK activation and IB degradation. NIH-
3T3 cells were pretreated with licochalcone A (20 M)
or DMSO (0.1%) for 1 h at 37°C after stimulation with
TNF- (10 ng/ml) for 10 min. A, whole cell lysates
were immunoblotted with antibodies recognizing TN-
FRI, TRADD, RIP1, TRAF2, IKK, IKK, IKK, p65,
p50, or -actin. B, cell lysates were immunoprecipi-
tated with anti-IKK antibody. IKK immunoprecipi-
tates were assayed for kinase activity using purified
GST-IB as a substrate (top). Immunoprecipitates
were immunoblotted with anti-IKK antibody (mid-
dle). The gel was stained with Coomassie Brilliant
Blue (CBB; bottom). C, whole cell lysates were immu-
noblotted with antibodies recognizing IB or -actin
as a control.
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polyacrylamide gel electrophoresis in Tris-glycine-EDTA buffer
and visualized by autoradiography.
NF-B Luciferase Assay. KF8 cells (5  104 cells) were cultured
in a 24-well plate and preincubated with various concentrations of
licochalone A or echinatin for 1 h at 37°C. After treatment with
TNF- (10 ng/ml) for 5 h, the cells were harvested and lysed in
passive lysis buffer (Promega, Madison, WI). Luciferase activity of
the lysates was determined using the luciferase reporter assay sys-
tem (Promega), according to the manufacturer’s instructions. NF-B-
dependent luciferase activity was normalized by the quantity of
protein for each sample, as described previously (Funakoshi-Tago et
al., 2008).
Cell Viability Analysis. NIH-3T3 cells (5  104) were preincu-
bated with various concentrations of licochalocne A for 1 h at 37°C.
After treatment with TNF- (10 ng/ml) for 12 h, the cells were
collected by trypsinization and then analyzed by trypan blue exclu-
sion tests using a cell viability analyzer (Beckman Coulter, Fuller-
ton, CA).
Immunofluorescence Assay. NIH-3T3 cells (5  105 cells) were
seeded on sterile coverslips in a six-well plate and pretreated with
licochalcone A (20 M) for 1 h after stimulation with TNF- (10 ng/
ml) for 30 min. After washing with PBS three times, the cells were
fixed in 4% paraformaldehyde for 10 min at room temperature and
washed with PBS three times. Cells on coverslips were permeabil-
ized in 0.2% (v/v) Triton X-100 for 5 min at room temperature. After
washing with PBS three times, the coverslips were blocked in PBS
containing 3% FBS for 5 min and incubated with an antibody recog-
nizing p65 (Santa Cruz Biotechnology, Inc.) diluted with PBS con-
taining 3% FBS at 1:200 dilution for 1 h at room temperature. After
washing with PBS three times, the coverslips were incubated with a
secondary antibody BODIPY FL anti-rabbit IgG (Invitrogen, Carls-
bad, CA) at 1:200 dilution for 1 h at room temperature. After washing
with PBS three times, the coverslips were mounted using
VECTASHIELD mounting medium with 4,6-diamidino-2-phenylin-
dole (Vector Laboratories, Burlingame, CA). Each coverslip was an-
alyzed on a BX50 microscope (Olympus, Tokyo, Japan), with Micro
DP70 software (Olympus) as described previously (Funakoshi-Tago
et al., 2008).
Immunoblot Analysis. Cells were washed with PBS and lysed in
lysis buffer containing 50 mM HEPES, pH 7.5, 0.5% Triton X-100,
100 mM NaF, 10 mM sodium phosphate, 4 mM EDTA, 2 mM
Na3VO4, 2 mM sodium molybdate, 2 g/ml aprotinin, and 2 g/ml
leupeptin. Cell lysates were centrifuged at 15,000 rpm at 4°C for 15
min to remove the debris, and the protein concentration was deter-
mined by Bradford assay (Bradford, 1976). Eluted proteins were
resolved by SDS-polyacrylamide gel electrophoresis and transferred
to polyvinylidene difluoride membranes. Membranes were probed
using the designated antibodies and visualized with the enhanced
chemiluminescence detection system (GE Healthcare, Chalfont St.
Giles, Buckinghamshire, UK), as described previously (Funakoshi-
Tago et al., 2003).
In Vitro IKK Assay. HEK293T cells (1.5  106 cells/60-mm dish)
were transfected with 2 g of pCMV5-Myc-IKK or pCMV5-Myc-
IKK (C179A) using FuGENE 6 (Roche Diagnostics, Indianapolis,
IN). NIH-3T3 cells (1  107 cells) were preincubated with licochal-
cone A (20 M) for 1 h at 37°C after stimulation with TNF- (10
ng/ml) for the indicated times. Cell lysates were immunoprecipitated
with anti-Myc antibody or anti-IKK antibody with protein G-Sepha-
rose (Zymed Laboratories, South San Francisco, CA) for 2 h at 4°C
and then washed three times with lysis buffer and twice with kinase
buffer (25 mM HEPES-NaOH, pH 7.5, 20 mM MgCl2, 20 mM -glyc-
erophosphate, 0.1 mM Na3VO4, 2 mM dithiothreitol, and 20 mM
p-nitrophenylphosphate). The kinase reaction in 20 l of kinase
buffer including [-32P]ATP was carried out with 1 g of GST-IB
as a substrate for 20 min at 30°C. Samples were resolved by SDS-
polyacrylamide gel electrophoresis, and phosphorylated GST-IB
was visualized by autoradiography, as described previously (Funa-
koshi-Tago et al., 2003).
RNA Isolation and Reverse Transcriptase-Polymerase
Chain Reaction. RNA was prepared using an RNA purification kit
(QIAGEN, Tokyo, Japan). Reverse transcription was performed us-
ing an oligo(dT)20 primer and 1 g of total RNA for first-strand cDNA
synthesis, as described previously (Funakoshi-Tago et al., 2003).
Polymerase chain reaction was performed at an annealing temper-
ature of 57°C with 22 amplification cycles. Polymerase chain reaction
products were resolved and electrophoresed in a 1.5% agarose gel in
Tris-acetic acid-EDTA buffer. Primer sequences were as follows:
GAPDH, 5-ACTCCACTCACGGCAAATTC-3 (upstream) and 5-
CCTTCCACAATGCCAAAGTT-3 (downstream); CCL2/MCP-1,
5-TGAGGTGG TTGTGGAAAAGG-3 (upstream) and 5-CCTGCT-
GTTCACAGTTGCC-3 (downstream); and CXCL1/KC, 5-TGGGGA-
CACCTTTTAGCATC-3 (upstream) and 5-GCCCATCGCCAAT-
GAGCTG-3 (downstream) (Funakoshi-Tago et al., 2003).
Enzyme-Linked Immunosorbent Assay. Cells (5  104) were
cultured in a 24-well plate and pretreated with chalcones (10 M) for
1 h at 37°C. After treatment with TNF- (10 ng/ml) for 24 h, the
supernatants were harvested and the amounts of CCL2/MCP-1 and
CXCL1/KC were determined using immunoassay kits (R&D Sys-
tems, Minneapolis, MN) (Funakoshi-Tago et al., 2008).
Purification of His6-Tagged Ubiquitin Conjugates.
HEK293T cells (1  105) were cotransfected with 1 g of pCMV5 or
pCMV5-RIP1 and 1 g of His6-tagged ubiquitin expression vector
using FuGENE6 (Roche Diagnostics) according to the manufactur-
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Fig. 4. Licochalcone A had no effect on the recruitment of IKK to TNFRI. A, NIH-3T3 cells were pretreated with licochalcone A (20 M) or DMSO
(0.1%) for 1 h at 37°C after stimulation with TNF- (10 ng/ml) for the indicated periods. Cell lysates were immunoprecipitated with anti-TNFRI
antibody. The immunoprecipitates were blotted with anti-RIP1 antibody, anti-IKK antibody, or anti-TNFRI antibody. B, HEK293T cells were
cotransfected with the indicated plasmids encoding RIP1 and/or His6-ubiquitin. At 48 h after transfection, cells were pretreated with licochalcone A
(20 M) or DMSO (0.1%) for 1 h at 37°C. The proteins from cell lysates were affinity-purified on nickel resin in buffer containing 8 M urea,
electrophoretically separated on denaturing gels containing SDS, and immunoblotted with anti-RIP1 antibody. Whole cell lysates prepared with lysis
buffer, as described under Materials and Methods, were subjected to immunoblotting with anti-RIP1 antibody (top). Whole cell lysates were
immunoblotted with anti-RIP1 antibody (bottom).
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transfected cell suspension was taken for direct protein immunoblot-
ting. The remaining cells were resuspended in lysis buffer containing
8 M urea, and His6-tagged proteins recovered with nickel beads
(QIAGEN, Valencia, CA) were eluted with imidazole, diluted with
sample buffer, and separated on gels containing SDS. After trans-
ferring to membranes, proteins were immunoblotted with anti-RIP1
antibody.
Results
Licochalcone A Significantly Inhibited TNF--In-
duced DNA Binding Activity of NF-B. Licochalcone A is
a major component of G. inflata (Fig. 1A) (Hatano et al., 1988;
Shibata, 2000). To investigate the anti-inflammatory effect of
licochalcone A, we evaluated its effect on TNF--induced
NF-B activation. First, we investigated its effect on NF-B
DNA binding activity by electrophoretic mobility shift assay
using nuclear extracts. When NIH-3T3 cells were treated
with various concentrations of licochalcone A for 1 h after
TNF- stimulation for 30 min, licochalcone A inhibited TNF-
-induced DNA binding activity of NF-B in a dose-depen-
dent manner. In contrast, licochalcone A alone had no effect
on NF-B activation (Fig. 1B). Next, to decide which type of
NF-B subunit was included in this protein-DNA complex,
we added specific antibodies against several NF-B subunits,
including p65, p50, and c-Rel. As shown in Fig. 1C, the
addition of anti-p65 antibody resulted in two sizes of super-
shifted protein-DNA complexes, indicating that this complex
includes p65, which could be involved in two active NF-B
complexes. Conversely, antibodies against p50 and c-Rel
failed to exhibit supershift activity (data not shown). As
shown in Fig. 1D, cell viability was not changed by treatment
with licochalcone A and/or TNF- stimulation, indicating
that the inhibition of NF-B activation by licochalcone A is
not attributable to its cytotoxicity.
Licochalcone A Significantly Inhibited TNF--In-
duced Nuclear Localization and Transcriptional Ac-
tivity of NF-B. Next, we investigated the effect of licoch-
alcone A on the TNF--induced nuclear translocation of
NF-B using nuclear extracts. As shown in Fig. 2A, TNF-
induced the accumulation of the p65 NF-B subunit in the
nucleus at 15 min. It was striking that licochalcone A signif-
icantly decreased the amount of nuclear NF-B after TNF-
stimulation. In addition, we performed immunofluorescence
staining to investigate the effect of licochalcone A on the
translocation of p65 NF-B subunit. Although most NF-B
p65 was translocated into the nucleus after TNF- stimula-
tion in cells treated with DMSO, licochalcone A clearly in-
hibited the TNF--induced translocation of NF-B p65 (Fig.
2B).
Furthermore, we evaluated the effect of licochalcone A on
NF-B transcriptional activation using KF8 cells, which sta-
bly express the NF-B luciferase reporter gene, as reported
previously (Funakoshi-Tago et al., 2008). As shown in Fig.
2C, TNF- induced NF-B transcriptional activation up to
approximately 12 times more than in unstimulated cells. It is
striking that licochalcone A potently inhibited TNF--in-
duced NF-B activation. The concentration of licochalcone A
up to 30 M had no effect on cell viability, as determined by
the trypan blue exclusion test (data not shown), suggesting













































Fig. 5. Cysteine 179 in IKK was involved in its inhibition by licochal-
cone A. A, NIH-3T3 cells were stimulated with TNF- (10 ng/ml) for 10
min, and cell lysates were prepared. IKK immunoprecipitates were
incubated with licochalcone A (20 M) or DMSO (0.1%) for 1 h at 37°C
and then assayed for kinase activity using purified GST-IB as a sub-
strate (top). Immunoprecipitates were immunoblotted with anti-IKK
antibody (middle). The gel was stained with Coomassie Brilliant Blue
(CBB; bottom). B, HEK293T cells were transfected with the indicated
plasmids encoding Myc-IKK or Myc-IKK mutant (C179A). At 48 h after
transfection, cell lysates were immunoprecipitated with anti-Myc anti-
body. The immunoprecipitates were incubated with licochalcone A (20
M) or DMSO (0.1%) for 1 h at 37°C and assayed for kinase activity using
purified GST-IB as a substrate (top). Immunoprecipitates were immu-





























































Fig. 6. Licochalcone A significantly inhibits TNF--induced expression
and secretion of CCL2 /MCP-1 and CXCL1/KC. A, NIH-3T3 cells were
pretreated with licochalcone A (10 M) or DMSO (0.1%) for 1 h at 37°C
after stimulation with TNF- (10 ng/ml) for the indicated periods. Total
RNA was used to perform RT-PCR with gene-specific primers to CCL2/
MCP-1, CXCL1/KC, or GAPDH. B, NIH-3T3 cells were pretreated with
licochalcone A (10 M) or DMSO (0.1%) for 1 h at 37°C after stimulation
with TNF- (10 ng/ml) for 14 h. CCL2/MCP-1 or CXCL1/KC in the
cultured supernatants was measured with a commercial ELISA kit (R&D
Systems). Data are shown as the mean  S.D. of three independent
experiments. , p  0.01.
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Licochalcone A Significantly Inhibited TNF--In-
duced IKK Activation and IB Degradation. To deter-
mine how licochalcone A inhibited NF-B activation induced
by TNF-, we investigated its effect on the expression levels
of major signaling molecules, which are required for the
TNF- signaling pathway. Upon TNF- stimulation, a
serine/threonine kinase, RIP1, and adaptor molecules
TRADD and TRAF2 were recruited to TNFRI (Rothe et al.,
1994; Hsu et al., 1995, 1996; Liu et al., 1996). Consequently,
NF-B is rapidly activated through activation of the IKK
complex (DiDonato et al., 1997; Mercurio et al., 1997; Zandi
et al., 1997; Yamaoka et al., 1998). However, the expression
levels of TNFRI, TRADD, RIP1, TRAF2, IKK, IKK, and
IKK were not changed in cells treated with 20 M licochal-
cone A in the absence and presence of TNF- stimulation
(Fig. 3A). We also analyzed the expression of the mature form
of TNFRI on the cell surface by flow cytometry analysis;
however, a similar level of cell surface TNFRI was observed
in cells untreated and treated with licochalcone A (data not
shown). Moreover, the expressions of the NF-B family, p65,
and p50 were also not affected by licochalcone A (Fig. 3A),
confirming that the inhibition of NF-B activation by licoch-
alcone A was not due to the altered expression of signaling
molecules in the TNF- signaling pathway.
Because IKK activation is a key step in NF-B activation
(DiDonato et al., 1997; Mercurio et al., 1997; Zandi et al.,
1997; Yamaoka et al., 1998), we next determined whether
licochalcone A inhibits TNF--induced IKK activation by in
vitro kinase assay. Cells were pretreated with licochalcone A
or DMSO as a control after TNF- stimulation. IKK complex
was immunoprecipitated with anti-IKK antibody, and IKK
activity was measured using GST-IB as a substrate. As
shown in Fig. 3B, licochalcone A significantly inhibited TNF-
-induced IKK activation. Furthermore, when the degrada-
tion of IB after TNF- stimulation was examined by im-
munoblotting, licochalcone A potently inhibited TNF--
induced IB degradation (Fig. 3C). Thus, these data
indicate that licochalcone A inhibited NF-B activation by
suppressing IKK activity.
Licochalcone A Had No Effect on the Recruitment of
IKK to TNFRI. It is known that IKK complex is recruited to
TNFRI in response to TNF- and then activated (Hsu et al.,
1996; DiDonato et al., 1997; Mercurio et al., 1997; Zandi et
al., 1997). Because IKK activity was severely inhibited by
licochalcone A (Fig. 3B), we also examined whether licochal-
cone A might affect the formation of TNFRI complex, includ-
ing RIP1 and IKKs; however, a coimmunoprecipitation assay
revealed that RIP1 and IKK were associated with TNFRI in
a TNF--dependent manner, even in cells treated with lico-
chalcone A (Fig. 4A).
A previous study showed that RIP1 is polyubiquitinated
after TNF- stimulation and that its polyubiquitination is
required for not only the recruitment but also the activation
of IKK complex (Liao et al., 2008); therefore, we next inves-
tigated whether the TNF--induced ubiquitination of RIP1 is
affected by licochalcone A. In this system, polyubiquitination
of RIP1 was induced by coexpression of His6-ubiquitin; how-
ever, licochalcone A had no effect on the ubiquitination of
RIP1 (Fig. 4B). Therefore, it is suggested that licochalcone A
inhibits TNF--induced IKK activation without abrogating
its recruitment to TNFRI.
Cysteine 179 in IKK Was Involved in Its Inhibition
by Licochalcone A. To investigate how licochalcone A sup-
presses IKK activity, we incubated whole cell lysates from
untreated cells and TNF--stimulated cells with anti-IKK
antibody. After being precipitated, immunocomplexes were
treated with licochalcone A or DMSO as a control. Although
DMSO had no effect on TNF--induced IKK activation, lico-
chalcone A significantly inhibited TNF--induced IKK acti-
vation (Fig. 5A).
IKK contains various cysteine residues and the cysteine
residue at position 179 in the activation loop has been shown
to be critical for its biological activity (Byun et al., 2006).
Therefore, to determine whether this cysteine is involved in
licochalcone A-mediated inhibition of IKK, HEK293T cells
were transfected with wild-type Myc-IKK or Myc-IKK mu-
tant with C179A mutation. After being precipitated using
anti-Myc antibody, the immunocomplexes were treated with
licochalcone A or DMSO as a control. It is interesting that
licochalcone A treatment significantly inhibited wild-type
IKK. In contrast, licochalcone A had no apparent effect on




































































Fig. 7. Echinatin fails to inhibit TNF--induced IKK activation and
NF-B activation. A, structure of echinatin. B, NIH-3T3 cells expressing
pNF-B-Luc (KF8 cells) were pretreated with different concentrations of
echinatin, 10 M licochalcone A, or DMSO (0.1%) for 1 h at 37°C after
stimulation with TNF- (10 ng/ml) for 5 h. NF-B-dependent luciferase
activity was normalized to the protein amounts. Data are the mean 
S.D. of the relative luciferase activities of pNF-B-Luc in four indepen-
dent experiments. , p  0.001. C, NIH-3T3 cells were stimulated with
TNF- (10 ng/ml) for 10 min, and cell lysates were prepared. IKK
immunoprecipitates were incubated with different concentrations of echi-
natin, 10 M licochalcone A, or DMSO (0.1%) for 1 h at 37°C and then
assayed for kinase activity using purified GST-IB as a substrate (top).
Immunoprecipitates were immunoblotted with anti-IKK antibody (mid-
dle). The gel was stained with Coomassie Brilliant Blue (CBB; bottom).
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ings suggest that cysteine 179 in IKK is a structure or part
of the structure that is necessary for inhibition by licochal-
cone A.
Licochalcone A Significantly Inhibited TNF--In-
duced Expression of Inflammatory Cytokines. RT-PCR
was performed to examine whether the inhibition of NF-B
by licochalcone A could be translated to its inability to acti-
vate target genes such as CCL2/MCP-1 and CXCL1/KC in
response to TNF-, When cells were stimulated with TNF-,
marked expressions of CCL2/MCP-1 mRNAs and CXCL1/KC
mRNA were induced at 2 h and detected until 4 h. In con-
trast, treatment with licochalcone A significantly inhibited
the TNF--induced expression of CCL2/MCP-1 and
CXCL1/KC (Fig. 6A). Licochalcone A potently and consis-
tently reduced the TNF--induced secretion of CCL2/MCP-1
and CXCL1/KC (Fig. 6B). These data suggest that licochal-
cone A shows anti-inflammatory activity by inhibiting
the expression of various TNF--induced inflammatory
cytokines.
Echinatin Failed to Inhibit TNF--Induced IKK Ac-
tivation and NF-B Activation. G. inflata contains not only
licochalcone A but also echinatin, which has a related structure
(Hatano et al., 1988). Licochalcone A is 5-(1,1-dimethy-2-prope-
nyl)-4,4-dihydroxy-2-methoxy chalcone (Fig. 1A). In contrast,
echinatin lacks a 5-(1,1-dimethy-2-propenyl) group (Fig. 7A). To
understand the precise mechanism of licochalcone A, we exam-
ined the correlation of its structure and activity using licochal-
cone A and echinatin. It is interesting that licochalcone A sig-
nificantly inhibited TNF--induced NF-B activation, but
echinatin had no effect on NF-B activation (Fig. 7B), indicating
that the 5-(1,1-dimethy-2-propenyl) group in licochalcone A is
important for the inhibition of NF-B. However, it is speculated
that the importance of 1,1-dimethy-2-propenyl group in NF-B
inhibition might be due to enhanced hydrophobility.
To examine these functions without considering the cell
permeability of each compound, IKK immunocomplexes were
treated with licochalcone A, echinatin, or DMSO as a control
in vitro. Whereas licochalcone A significantly inhibited TNF-
-induced IKK activation, echinatin had no effect on TNF--
induced IKK activation even at high concentrations (Fig. 7C);
therefore, it was confirmed that echinatin failed to inhibit
TNF--induced IKK activation. As shown in Fig. 8, echinatin
had no effect on TNF--induced expression and the produc-
tion of inflammatory cytokines, such as CCL2/MCP-1 and
CXCL1/KC. Taken together, the 1,1-dimethy-2-propenyl
group in licochalcone A is required for NF-B inhibition and
anti-inflammatory effects.
Discussion
In the current study, we showed that licochalcone A sig-
nificantly inhibited TNF--induced NF-B activation
through the inhibition of IKK activation. Licochalcone A is a
major flavonoid isolated from the root of G. inflata. The
several reports indicate that licochalcone A harbors potent
anti-inflammatory effects; however, the detailed molecular
mechanism of its anti-inflammatory activity has not been
explored. TNF- plays a pivotal role in immune and inflam-
matory responses by inducing many inflammatory cytokines.
In addition, many previous studies have reported the essen-
tial role of the activation of mitogen-activated protein
kinases and NF-B in these TNF--induced cytokine expres-
sions. Although licochalcone A effectively diminished TNF-
-induced inflammatory cytokine expression, it had no effect
on TNF--induced activation of the mitogen-activated pro-
tein kinase family, c-Jun NH2-terminal kinase, and p38 (data
not shown). Therefore, the inhibition of cytokine expression
by licochalcone A seems to have occurred from its specific
inhibitory effects on NF-B activation.
In the previous report, we also discovered an inhibitory
effect of licochalcone A on LPS-induced NO production
through the inhibition of NF-B activation (Furusawa et al.,
2009). In the LPS signaling pathway, licochalcone A specifi-
cally inhibits NF-B activation by suppressing the phosphor-
ylation of p65; however, it failed to inhibit LPS-induced ac-
tivation of IKK complex. Our findings indicate that, in the
LPS signaling pathway, licochalcone A markedly inhibited
the phosphorylation of p65 at serine 276 and then reduced
NF-B transactivation by preventing the interaction of























































































Fig. 8. Echinatin has no effect on TNF--
induced expression and secretion of CCL2
/MCP-1and CXCL1/KC. A, NIH-3T3 cells
were pretreated with different concentra-
tions of echinatin, licochalcone A (10 M),
or DMSO (0.1%) for 1 h at 37°C after
stimulation with TNF- (10 ng/ml) for
2 h. Total RNA was used to perform RT-
PCR with gene-specific primers to CCL2/
MCP-1, CXCL1/KC, or GAPDH. B, NIH-
3T3 cells were pretreated with different
concentrations of echinatin, licochalcone
A (10 M), or DMSO (0.1%) for 1 h at 37°C
after stimulation with TNF- (10 ng/ml)
for 14 h. CCL2/MCP-1 or CXCL1/KC in
the cultured supernatants was measured
with a commercial ELISA kit (R&D Sys-
tems). Data are shown as the mean 
S.D. of three independent experiments.
, p  0.01.
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showed that licochalcone A effectively inhibits TNF--in-
duced activation of IKK complex, which is completely differ-
ent from the LPS data. There is currently insufficient expla-
nation of the different inhibitory mechanisms in the LPS
signaling pathway and TNF- signaling pathway.
IKK contains an N-terminal protein kinase domain and
leucine zipper and helix-loop-helix motifs in its C-terminal
half (Zandi et al., 1997). The cysteine 179 residue in the
activation loop of IKK is known to be the target site for IKK
inhibitors (Rossi et al., 2000). It has been reported that
curcumin (diferuloylmethane) and butein (3,4,2,4-tetrahy-
droxychalcone) inhibited NF-B activation through the direct
inhibition of IKK via cysteine 179 (Jobin et al., 1999; Pan-
dey et al., 2007). Curcumin is a naturally occurring product
isolated from rhizomes of the plant Curcuma longa, and
butein has been identified from numerous plants, including
the stem bark of cashews (Semecarpus anacardium), the
heartwood of Dalbergia odorifera, and traditional Chinese
and Tibetan medicinal herbs Caragana jubata and Rhus
verniciflua Stokes (Jobin et al., 1999; Pandey et al., 2007). In
addition, Park et al. (2007) reported that melittin also exhib-
ited inhibitory effects on NF-B activation through direct
interaction with IKK and IKK.
It is interesting that we also observed that licochalcone A
inhibited the activity of wild-type IKK but not an IKK
mutant (C179A) (Fig. 5B), suggesting that cysteine 179 in
IKK is also necessary for IKK inhibition by licochalcone A;
however, we have no evidence supporting the direct interac-
tion between IKKs and licochalcone A. In the current study,
we observed that licochalcone A is also effective on immuno-
precipitated IKK complex (Fig. 5A), suggesting that the tar-
get molecule of licochalcone A should be included in immu-
noprecipitated protein complex. Considering the different
inhibitory mechanisms of licochalcone A in the LPS- and
TNF--induced signaling pathways leading to NF-B activa-
tion, this observation could be a valuable indication. Com-
pared with signaling cascades stimulating IKK complexes,
LPS and TNF- use different signaling components. TNF--
induced IKK activation requires the recruitment of several
cytosolic proteins, RIP1 and TRAF2 to TNFRI, which are
required for the recruitment and activation of IKK (Hsu et
al., 1996; Mercurio et al., 1997). Furthermore, Liao et al.
(2008) showed that polyubiquitination of RIP1 is required for
the recruitment of IKK to TNFRI and IKK activation, and
this is not observed in the LPS signaling pathway (Chow et
al., 1999). However, licochalcone A had no effect on the ubiq-
uitination of RIP1 (Fig. 4B) or on the TNF--induced recruit-
ment of IKK to TNFRI (Fig. 4A), suggesting that the tar-
geting molecule of licochalcone A should exist downstream of
RIP1/TRAF2, maybe in the IKK complex. In addition, the
different cells used in the two experiment systems could be
another explanation. Whereas we used murine fibroblasts,
NIH-3T3 cells, to examine TNF- signaling in this study, a
murine macrophage cell line, RAW264.7, was used to analyze
the LPS signaling pathway, as shown previously. Although it
has been reported that TNFRI is expressed ubiquitously
(Heller et al., 1990; Ryffel et al., 1991), NF-B activation was
not induced when RAW264.7 cells were stimulated with
TNF- (data not shown). Our current results suggest that
signaling molecules leading to NF-B activation in the
TNF- signaling pathway might be deficient in cells and that
this molecule could be an essential factor for exhibiting sen-
sitivity against licochalcone A. DiDonato et al. (1997) puri-
fied a 900-kDa protein kinase complex harboring the ability
to phosphorylate IB; therefore, it is expected that the IKK
complex could consist of a number of unknown molecules in
addition to IKK, -, -, and so on.
Licochalcone A is a 5-(1,1-dimethy-2-propenyl)-4,4-dihy-
droxy-2-methoxy chalcone (Fig. 1A). To understand the pre-
cise mechanism of licochalcone A by examining the correla-
tion of the structure and its activity, we compared the effect
of echinatin, which is also contained in G. inflata. It is inter-
esting that although licochalcone A significantly inhibited
TNF--induced NF-B activation, echinatin had no effect on
the TNF- signaling pathway. To consider the different ef-
fects of these compounds, log P of licochalcone A and echi-
natin was calculated by Spartan’04 (Wavefunction, Inc., Ir-
vine, CA). Log P is an index showing the hydrophobility of
chemical compounds and the calculated log P were 4.71 and
2.92, respectively. Thus, it is easily speculated that echinatin
had difficulty penetrating the cell to exhibit its activity be-
cause of its low hydrophobicity. However, when the effect of
echinatin on IKK activity was examined in vitro, IKK activity
was not inhibited by the addition of echinatin (Fig. 7C).
These data clearly showed that echinatin was not able to
inhibit IKK activation and that the 1,1-dimethy-2-propenyl
group is required for IKK inhibition. Because NF-B plays a
central role in inflammation, a study of the compounds re-
lated to licochalcone A would provide clues to develop more
specific therapeutic drugs against inflammatory diseases.
Acknowledgments
We thank Dr. Dirk Bohmann for providing the His6-tagged ubiq-
uitin expression vector. We also thank S. Tanifuji, K. Nakamura, and
Y. Sugita for technical help.
References
Barrett K, Taylor-Fishwick DA, Cope AP, Kissonerghis AM, Gray PW, Feldmann M,
and Foxwell BM (1991) Cloning, expression and cross-linking analysis of the
murine p55 tumor necrosis factor receptor. Eur J Immunol 21:1649–1656.
Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram
quantities of protein utilizing the principle of protein-dye binding. Anal Biochem
72:248–254.
Byun MS, Choi J, and Jue DM (2006) Cysteine-179 of IkappaB kinase beta plays a
critical role in enzyme activation by promoting phosphorylation of activation loop
serines. Exp Mol Med 38:546–552.
Chen G and Goeddel DV (2002) TNF-R1 signaling: a beautiful pathway. Science
296:1634–1635.
Chen M, Christensen SB, Blom J, Lemmich E, Nadelmann L, Fich K, Theander TG,
and Kharazmi A (1993) Licochalcone A, a novel antiparasitic agent with potent
activity against human pathogenic protozoan species of Leishmania. Antimicrob
Agents Chemother 37:2550–2556.
Chow JC, Young DW, Golenbock DT, Christ WJ, and Gusovsky F (1999) Toll-like
receptor-4 mediates lipopolysaccharide-induced signal transduction. J Biol Chem
274:10689–10692.
DiDonato JA, Hayakawa M, Rothwarf DM, Zandi E, and Karin M (1997) A cytokine-
responsive IkappaB kinase that activates the transcription factor NF-kappaB.
Nature 388:548–554.
DiDonato J, Mercurio F, Rosette C, Wu-Li J, Suyang H, Ghosh S, and Karin M (1996)
Mapping of the inducible IkappaB phosphorylation sites that signal its ubiquiti-
nation and degradation. Mol Cell Biol 16:1295–1304.
Fukai T, Marumo A, Kaitou K, Kanda T, Terada S, and Nomura T (2002) Anti-
Helicobacter pylori flavonoids from licorice extract. Life Sci 71:1449–1463.
Funakoshi-Tago M, Shimizu T, Tago K, Nakamura M, Itoh H, Sonoda Y, and
Kasahara T (2008) Celecoxib potently inhibits TNFalpha-induced nuclear trans-
location and activation of NF-kappaB. Biochem Pharmacol 76:662–671.
Funakoshi-Tago M, Sonoda Y, Tanaka S, Hashimoto K, Tago K, Tominaga S, and
Kasahara T (2003) Tumor necrosis factor-induced nuclear factor B activation is
impaired in focal adhesion kinase-deficient fibroblasts. J Biol Chem 278:29359–
29365.
Furuhashi I, Iwata S, Shibata S, Sato T, and Inoue H (2005) Inhibition by licochal-
cone A, a novel flavonoid isolated from liquorice root, of IL-1beta-induced PGE2
production in human skin fibroblasts. J Pharm Pharmacol 57:1661–1666.
Furusawa J, Funakoshi-Tago M, Tago K, Mashino T, Inoue H, Sonoda Y, and
Kasahara T (2009). Licochalcone A significantly suppresses LPS signaling path-
752 Funakoshi-Tago et al.
way through the inhibition of NF-B p65 phosphorylation at serine 276. Cell
Signal 21:778–785.
Haraguchi H, Ishikawa H, Mizutani K, Tamura Y, and Kinoshita T (1998) Antioxi-
dative and superoxide scavenging activities of retrochalcones in Glycyrrhiza in-
flata. Bioorg Med Chem 6:339–347.
Hatano T, Kagawa H, Yasuhara T, and Okuda T (1988) Two new flavonoids and
other constituents in licorice root: their relative astringency and radical scaveng-
ing effects. Chem Pharm Bull (Tokyo) 36:2090–2097.
Hayden MS and Ghosh S (2008) Shared principles in NF-kappaB signaling. Cell
132:344–362.
Heller RA, Song K, Onasch MA, Fischer WH, Chang D, and Ringold GM (1990)
Complementary DNA cloning of a receptor for tumor necrosis factor and demon-
stration of a shed form of the receptor. Proc Natl Acad Sci U S A 87:6151–6155.
Hsu H, Huang J, Shu HB, Baichwal V, and Goeddel DV (1996) TNF-dependent
recruitment of the protein kinase RIP to the TNF receptor-1 signaling complex.
Immunity 4:387–396.
Hsu H, Xiong J, and Goeddel DV (1995) The TNF receptor 1-associated protein
TRADD signals cell death and NF-kappa B activation. Cell 81:495–504.
Jobin C, Bradham CA, Russo MP, Juma B, Narula AS, Brenner DA, and Sartor RB
(1999) Curcumin blocks cytokine-mediated NF-kappa B activation and proinflam-
matory gene expression by inhibiting inhibitory factor I-kappa B kinase activity.
J Immunol 163:3474–3483.
Liao W, Xiao Q, Tchikov V, Fujita K, Yang W, Wincovitch S, Garfield S, Conze D,
El-Deiry WS, Schütze S, et al. (2008) CARP-2 is an endosome-associated ubiquitin
ligase for RIP and regulates TNF-induced NF-kappaB activation. Curr Biol 18:
641–649.
Liu ZG (2003) Adding facets to TNF signaling. The JNK angle. Mol Cell 12:795–796.
Review.
Liu ZG, Hsu H, Goeddel DV, and Karin M (1996) Dissection of TNF receptor 1
effector functions: JNK activation is not linked to apoptosis while NF-kappaB
activation prevents cell death. Cell 87:565–576.
Mercurio F, Zhu H, Murray BW, Shevchenko A, Bennett BL, Li J, Young DB,
Barbosa M, Mann M, Manning A, et al. (1997) IKK-1 and IKK-2: cytokine-
activated IkappaB kinases essential for NF-kappaB activation. Science 278:860–
866.
Mukaida N, Mahe Y, and Matsushima K (1990) Cooperative interaction of nuclear
factor-kappa B- and cis-regulatory enhancer binding protein-like factor binding
elements in activating the interleukin-8 gene by pro-inflammatory cytokines.
J Biol Chem 265:21128–21133.
Palombella VJ, Rando OJ, Goldberg AL, and Maniatis T (1994) The ubiquitin-
proteasome pathway is required for processing the NF-kappa B1 precursor protein
and the activation of NF-kappa B. Cell 78:773–785.
Pandey MK, Sandur SK, Sung B, Sethi G, Kunnumakkara AB, and Aggarwal BB
(2007) Butein, a tetrahydroxychalcone, inhibits nuclear factor (NF)-B and NF-
B-regulated gene expression through direct inhibition of IB kinase  on cys-
teine 179 residue. J Biol Chem 282:17340–17350.
Park HJ, Son DJ, Lee CW, Choi MS, Lee US, Song HS, Lee JM, and Hong JT (2007)
Melittin inhibits inflammatory target gene expression and mediator generation
via interaction with IkappaB kinase. Biochem Pharmacol 73:237–247.
Ping D, Boekhoudt GH, Rogers EM, and Boss JM (1999) Nuclear factor-kappa B p65
mediates the assembly and activation of the TNF-responsive element of the mu-
rine monocyte chemoattractant-1 gene. J Immunol 162:727–734.
Rossi A, Kapahi P, Natoli G, Takahashi T, Chen Y, Karin M, and Santoro MG (2000)
Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of IkappaB
kinase. Nature 403:103–108.
Rothe M, Wong SC, Henzel WJ, and Goeddel DV (1994) A novel family of putative
signal transducers associated with the cytoplasmic domain of the 75 kDa tumor
necrosis factor receptor. Cell 78:681–692.
Ryffel B, Brockhaus M, Greiner B, Mihatsch MJ, and Gudat F (1991) Tumour
necrosis factor receptor distribution in human lymphoid tissue. Immunology 74:
446–452.
Shibata S (2000) A drug over the millennia: pharmacognosy, chemistry, and phar-
macology of licorice. Yakugaku Zasshi 120:849–862.
Wajant H, Pfizenmaier K, and Scheurich P (2003) Tumor necrosis factor signaling.
Cell Death Differ 10:45–65.
Yamaoka S, Courtois G, Bessia C, Whiteside ST, Weil R, Agou F, Kirk HE, Kay RJ,
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